Advanced Enzyme Ipo Subscription

Advanced enzyme ipo subscription

India’s biggest enzyme company Advanced Enzyme Technologies Ltd IPO will be opened on 20th July, 2016.

November 5th 2020 cryptocurrency

Advanced Enzyme Technologies is planning to raise 412 Cr with this IPO. Issue price of this IPO is fixed in the range of Rs 880 to Rs 896.

Advanced enzyme ipo subscription

Let’s explore and try to find out an answer that Advanced Enzyme Technologies Ltd IPO is worth for investment or not.

Advanced Enzyme Technologies Ltd is engaged in research, development, manufacturing and marketing of Healthcare, Nutrition and Bio-processing products.

Advance Enzyme operates in two primary business verticals namely Healthcare & Nutrition (human and animal) and Bio-Processing (food and non-food).

Advanced Enzyme Technologies Ltd IPO Review

Issue Detail of Advance Enzyme Technologies

  • Issue Size – 412 Cr
  • IPO opens on – 20th July, 2016
  • IPO closes on – 22nd July, 2016
  • Face Value – Rs 10 per Equity Share
  • Issue Price: Rs.

    Swing trade stock options

    880 – Rs. 896 Per Equity Share

  • Market Lot: 16 Shares
  • Minimum Order Quantity: 16 Shares
  • Listing At: BSE, NSE
  • Download Advanced Enzyme Technologies Ltd IPO Prospectus

Objective of Issue

  • Prepayment / repayment of certain loans availed by its fully-owned subsidiary Advanced Enzymes USA.
  • Exit route for existing investors
  • General Corporate purpose

Also Read – NFO – Important Points to consider before investing in NFO

Advance Enzyme Technologies Ltd Financials

Advance Enzyme Technologies financial performance over past five years is extremely good.

The top line of the company is expanding every year.

Post navigation

Between FY 2012 and FY 2016, Advance Enzyme Technologies top line grew at CAGR of 14.4%. Net profit margin of company is also increasing YOY.

Positive Points about Advanced Enzyme Technologies Ltd

  • Advanced Enzyme Technologies Ltd is 2nd largest enzyme company of India.
  • This company deals in 400 proprietary products from 60 enzymes.
  • The Company has 13 patents registered in its name and applications for registration of 4 patents are pending.
  • Advanced Enzyme Technologies has 700 global customers across 50 countries around the world.
  • The Company has very good R&D team consist of over 55 scientists, microbiologists, engineers, food technologists and biotechnologists.
  • Advance Enzyme Technologies has specialized business model with high entry barriers.
  • Diversified product range and wide customer base.
  • Experience and strong management team.
  • Financial stability and stable cash flow.

Risk factors

  • There are certain legal proceedings against company and group of companies.

    Advanced Enzyme management explains business model

    Any adverse decision in such proceedings may have a material adverse effect on the business, results of operations and financial condition.

  • There are certain criminal matter against non executive and nominee director of company. Failure in this proceeding may have adverse impact on reputation of company.
  • Lot of dependency on foreign subsidiaries especially in North America.
  • Historical revenue is significantly depended on top five product group.

    Advanced enzyme ipo subscription

    Any reduction in demand or sell of these products will adversely impact on business.

  • Majority of business is export related and income is depended on foreign currency and it involves risk of currency fluctuations.

Should you invest in Advanced Enzyme Technologies Ltd IPO?

Advanced Enzyme Technologies Ltd deals in multiple proprietary products.

Company has strong customer base in the global market. The company is exhibiting very strong financial performance and balance sheet.

Advanced enzyme ipo subscription

Strong management team and promoters credibility is another plus point for this IPO.

This is first IPO in enzyme segment. Looking at track record and future business prospects it is advisable to invest in Advanced Enzyme Technologies Ltd IPO.

Advanced enzyme ipo subscription